Virtual Library

Start Your Search

Y. Gunaydin



Author of

  • +

    P1.10 - Poster Session 1 - Chemotherapy (ID 204)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.10-007 - Biweekly Cisplatin And Gemcitabine As First-Line Treatment in Advanced Non-Small Cell Lung Cancer (ID 671)

      09:30 - 09:30  |  Author(s): Y. Gunaydin

      • Abstract

      Background
      Non-small cell lung cancer (NSCLC) is the most common cancer worldwide. Majority of the patients present with advanced disease. For patients with good performance status, palliative chemotherapy consisting of a platinum-containing doublet has become Standard of care. Cisplatin plus gemcitabine is a viable option in the treatment of metastatic NSCLC. Biweekly use of this regimen has been found to be effective and tolerable in various cancers. Moreover, this schedule offers a more convenient way of administration. We retrospectively evaluated the efficacy and tolerability of this regimen in advanced NSCLC patients.

      Methods
      Medical records of advanced NSCLC patients who were treated with first-line biweekly cisplatin + gemcitabine chemotherapy were analyzed retrospectively. Cisplatin 50 mg/m2 and gemcitabine 1000 mg/m2 were given on day 1 of every 14 days of the cycle. Response rates, survival outcomes and toxicities were recorded.

      Results
      A total of 109 patients were evaluated in six centers of Anatolian Society of Medical Oncology. Of those, 94 patients were men (86%) and 15 were women (14%). The median age was 58 years (range, 25-82). Most of the patients had adenocarcinoma (n=62, 57%). All of them had ≤2 ECOG PS. Median 7 cycles therapy were given (range, 2-12). Patients were evaluated for response usually after every 4 cycles. There was no complete response. Forty-five patients (41%) achieved partial response (PR). Stable disease was observed in 27% of the patients leading to an overall clinical benefit rate of 68%. Median progression-free survival (PFS) was 5.9 months. Median overall survival (OS) was 12.6 months. Eight patients died due to progression during therapy. The most common non-hematologic toxicities were nausea and vomiting. Grade 3/4 toxicity was detected in eight (7%) patients. They were four anemias, two neutropenias, one vomiting and one nephropathy. In all grades, the most common hematologic toxicity was anemia (48%). Neutropenia was seen in 21% of the cases, but only one patient had febrile neutropenia. One patient had to discontinue therapy due to grade 2 nephropathy.

      Conclusion
      Biweekly cisplatin and gemcitabine is an effective and tolerable regimen in the first-line treatment of NSCLC.

  • +

    P1.22 - Poster Session 1 - Epidemiology, Etiology (ID 166)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Prevention & Epidemiology
    • Presentations: 1
    • +

      P1.22-002 - Non-small cell lung cancer in young patients: Clinicopathological features (ID 670)

      09:30 - 09:30  |  Author(s): Y. Gunaydin

      • Abstract

      Background
      Non-small cell lung cancer (NSCLC) is the most common cancer worldwide. NSCLC is strongly related to age. Its incidence increases with advancing age and the median age at diagnosis is 70 years. Less than 5% of all NSCLC is seen before 40 years of age. Furthermore, young patients have different characteristics compared with older patients. In this study, the clinical features of patients less than 40 years of age were analyzed.

      Methods
      Medical records of patients diagnosed as having NSCLC between March 2000 and March 2013 were retrospectively examined in 17 institutions of Anatolian Society of Medical Oncology. Epidemiological data such as age, gender and smoking history was collected. Additionally, histological subtype, ECOG performance status, stage, number of organ metastasis, presence of cranial metastases were analyzed.

      Results
      A total of 210 patients were evaluated. Median age was 35 years (range, 18-40). The majority of the patients were males (148 males and 62 females). There were 120 patients with a history of smoking. Seventy-eight patients were non-smokers and twelve were unknown. Majority of the patients (64%) had stage IV disease at presentation. Most of the patients had good performance status. Half of these patients had two or more organ metastasis (53%). Cranial metastases were detected in 55 patients. Adenocarcinoma was the most common histological subtype (57%). Other subtypes were squamous cell carcinoma (20%) and unclassified (20%). In stage IV disease, adenocarcinoma was more frequent (64%). There was no association between histopathologic subtype and smoking history. Median overall survival (OS) of the entire cohort was 15.1 months. Median OS was similar to the literature data (stage II: 45.8 months, IIIA: 44.4 months, IIIB: 21.1 months and stage IV: 9.9 months).

      Conclusion
      Adenocarcinoma was more common in the younger patients. These patients had advanced disease and good performance status at presentation. However, survival was not better than older patients based on historical literature data.